Speaking to shareholders at the Zoetis
Inc. (NYSE:ZTS) annual meeting today in Short Hills, N.J., Chief
Executive Officer Juan Ramón Alaix discussed the company’s strong
performance over the past five years and strategies for continued growth
as the leader in the global animal health industry.
“In 2017, we delivered our fifth consecutive year of operational revenue
growth and increased profitability based on deep relationships with
customers, innovative research and development, and high-quality
manufacturing and supply,” said Alaix. “As we look to the future, we are
energized by the growth opportunities in animal health that will keep us
on the path of continued industry leadership, and we remain firmly
committed to delivering on the long-term value proposition that has
generated returns for our investors.”
Zoetis Chairman Michael McCallister presided over the business portion
of the meeting and shareholder voting. Preliminary results of
shareholder voting from the meeting are as follows:
-
Sanjay Khosla, Willie M. Reed, Linda Rhodes and William C. Steere, Jr.
have been elected as directors for three-year terms.
-
Shareholders approved, on an advisory basis, the compensation of the
company’s named executive officers.
-
Shareholders ratified and approved the selection of KPMG LLP as the
company’s independent registered public accounting firm for fiscal
year 2018.
The final results of the shareholder voting are subject to verification
by the independent election inspector; results will be filed in a Form
8-K and available on the Investor section of the Zoetis website.
A full replay of the meeting will be made available at http://investor.zoetis.com/events-presentations,
along with the presentation materials from the event.
About Zoetis
Zoetis
is the leading animal health company, dedicated to supporting its
customers and their businesses. Building on more than 60 years of
experience in animal health, Zoetis discovers, develops, manufactures
and markets veterinary vaccines and medicines, complemented by
diagnostic products, genetic tests, biodevices and a range of services.
Zoetis serves veterinarians, livestock producers and people who raise
and care for farm and companion animals with sales of its products in
more than 100 countries. In 2017, the company generated annual revenue
of $5.3 billion with approximately 9,000 employees. For more
information, visit
www.zoetis.com
.
DISCLOSURE NOTICES
Forward-Looking Statements
: This
press release contains forward-looking statements, which reflect the
current views of Zoetis with respect to business plans or prospects,
future operating or financial performance, future guidance, and other
future events. These statements are not guarantees of future performance
or actions. Forward-looking statements are subject to risks and
uncertainties. If one or more of these risks or uncertainties
materialize, or if management's underlying assumptions prove to be
incorrect, actual results may differ materially from those contemplated
by a forward-looking statement. Forward-looking statements speak only as
of the date on which they are made. Zoetis expressly disclaims any
obligation to update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise. A further list
and description of risks, uncertainties and other matters can be found
in our Annual Report on Form 10-K for the fiscal year ended December 31,
2017, including in the sections thereof captioned “Forward-Looking
Statements and Factors That May Affect Future Results” and “Item 1A.
Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current
Reports on Form 8-K. These filings and subsequent filings are available
online at
www.sec.gov
,
www.zoetis.com
,
or on request from Zoetis.
Zoetis
Media:
Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com
or
Investor:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com